8-K: Matinas BioPharma Merges with GH Power, Sells LNC Platform

Matinas BioPharma Holdings, Inc. announces a strategic business combination with GH Power Inc. to form a clean energy company, alongside the sale of its LNC platform and MAT2203 to Azurity Pharmaceuticals.

Summary

• Matinas BioPharma Holdings, Inc. (MTNB) has entered into a Business Combination Agreement with GH Power Inc. to create a new publicly traded company focused on critical minerals and clean energy, to be named GH Power International.
• The transaction involves GH Power merging with a subsidiary of a new Ontario corporation, followed by Matinas merging with another subsidiary of the same new corporation, with Matinas becoming a subsidiary of GH Power International.
• GH Power specializes in modular reactor systems that convert scrap metals and water into high-purity alumina, clean hydrogen, and thermal energy.
• Matinas BioPharma Nanotechnologies, Inc., including its lipid nano-crystal (LNC) technology platform and lead product candidate MAT2203, is being sold to Azurity Pharmaceuticals for $4.0 million upfront, with potential for up to $17.5 million in milestones and royalties.
• The company also completed a Series D Convertible Preferred Stock financing, raising $575,000, and a warrant inducement, raising approximately $2.6 million from the exercise of existing warrants.
• The business combination is expected to close in the fourth quarter of 2026, subject to stockholder approvals and other customary closing conditions.
• Following the business combination, existing GH Power equityholders are expected to own approximately 91% of the new entity, and existing Matinas equityholders approximately 9%.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as it represents a strategic pivot with potential for growth in the clean energy sector, but also involves the divestiture of the company's biopharmaceutical assets and a significant dilution for existing Matinas shareholders in the new entity.

Positives

• Creation of a new, publicly traded clean energy company focused on critical minerals and green hydrogen.
• GH Power's proprietary technology addresses growing demand for modular carbon-free energy and industrial decarbonization.
• Sale of the LNC platform and MAT2203 to Azurity provides upfront cash and potential future milestone payments and royalties.
• The business combination is expected to provide access to public capital markets to accelerate growth and commercialization.
• The Series D financing and warrant inducement provided immediate capital for working capital and general corporate purposes.
• The combined company is expected to leverage public market access for strategic growth and project development.

Negatives

• Matinas BioPharma shareholders will hold a minority stake (approximately 9%) in the combined entity.
• The sale of the LNC platform and MAT2203 represents a divestiture of Matinas's biopharmaceutical assets.
• The business combination is subject to numerous closing conditions, including stockholder approvals and financing completion.
• The company will require significant capital to execute its growth strategy post-combination.
• The terms of the sale of Matinas BioPharma Nanotechnologies, Inc. mean former Series A preferred stockholders will receive 7.5% of amounts received from Azurity.

Risks

• The business combination and stock sale may not be completed in a timely manner or at all.
• Failure to satisfy closing conditions, including stockholder approvals and the GH Power financing.
• The combined company may not realize the anticipated benefits of the business combination.
• Risks associated with the commercialization and deployment of GH Power's technology.
• Potential for legal proceedings following the announcement of the transactions.
• The company's ability to secure future financing and manage its cash burn.
• Regulatory approvals and market acceptance of GH Power's technologies.

Future Outlook

The business combination is expected to create a publicly traded, advanced clean energy company focused on modular carbon-free energy, green hydrogen, critical materials, and industrial decarbonization. The combined entity aims to accelerate commercialization, project development, and strategic growth, leveraging public market access for capital. The sale of the LNC platform and MAT2203 allows Matinas to focus on this new strategic direction.

Management Comments

• "Becoming a publicly traded company is expected to strengthen our access to capital, enhance our strategic visibility, and accelerate the commercialization of our proprietary modular reactor technology."
• "We are focused on deploying our technology across industrial applications, expanding our strategic partnerships and entering new markets where demand for critical minerals, behind-the-meter power and green hydrogen continues to grow."
• "We believe this transaction positions GH Power to execute on its commercial pipeline and deliver sustainable long-term value for customers and shareholders."
• "Following a comprehensive review of strategic alternatives, our Board concluded that this transaction represents a compelling strategic opportunity to maximize long-term value for our stockholders."
• "We believe this transaction positions our stockholders to participate in an innovative company focused on advanced clean energy, green hydrogen and critical minerals markets that are attracting significant global investment and are expected to experience substantial long-term growth while also unlocking the value of our LNC technology platform and MAT2203 through their sale to Azurity."

Industry Context

StockSavvy.ai notes that this transaction reflects a significant shift in Matinas BioPharma's strategy, moving away from its biopharmaceutical focus towards the rapidly growing clean energy and critical materials sectors, driven by GH Power's technology. This aligns with broader industry trends towards decarbonization, green hydrogen production, and onshoring of critical mineral supply chains.

Comparison to Industry Standards

• The valuation of Matinas at $24.7 million and GH Power at $250 million for the business combination is subject to adjustments based on capital raised and relative capitalization, which are standard in such SPAC-like transactions.
• The upfront payment of $4.0 million and potential milestones up to $17.5 million for the sale of a drug candidate and technology platform is within the typical range for early-stage asset divestitures, though the royalty component adds long-term upside potential.
• The $15.0 million minimum financing requirement for GH Power is a common condition in business combinations to ensure sufficient capital for post-merger operations and growth.

Management Changes

Corporate Governance

Legal Proceedings

• Potential legal proceedings against the Company, GH Power, Pubco, Azurity, or others following the announcement of the transactions.

Related Party Transactions

• Former financial advisor to Matinas is entitled to a $2.0 million cash fee and $2.0 million in Pubco Common Shares upon closing of the Business Combination.
• Former holders of Matinas's Series A Preferred Stock are entitled to 7.5% of amounts received by Matinas from Azurity in the Stock Sale.

Stakeholder Impact

• Matinas shareholders will receive 0.1 of a GH Power International share for each Matinas share, resulting in a significant ownership dilution (approx. 9% of the combined entity).
• GH Power equityholders will own the majority stake (approx. 91%) in the combined entity.
• Employees of Matinas BioPharma Nanotechnologies, Inc. will transfer to Azurity Pharmaceuticals.
• Creditors of Matinas may be impacted by the strategic shift and asset sale, depending on the terms of existing debt.
• The company's CEO, Jerome D. Jabbour, has an amended employment agreement that makes a retention bonus payable upon the closing of the business combination.

Next Steps

• Obtain required stockholder approvals for the business combination and related transactions.
• Complete the $15.0 million financing for GH Power.
• File the Form F-4 registration statement with the SEC.
• Obtain listing approval for GH Power International's common shares on the NYSE American.
• Complete the business combination and the stock sale, expected in Q4 2026.

Key Dates

Recommendation

The transaction represents a significant strategic shift for Matinas BioPharma, moving into the clean energy sector while divesting its biopharmaceutical assets. While the clean energy sector offers growth potential, existing Matinas shareholders face substantial dilution and a change in the company's core business. The success of the combined entity hinges on GH Power's technology execution and market adoption, alongside the capital raised. Given the uncertainties and the minority stake for current shareholders, a 'hold' recommendation is prudent pending further developments and clarity on the combined company's performance.

Keywords

business combination, GH Power, Matinas BioPharma, clean energy, green hydrogen, critical minerals, Azurity Pharmaceuticals, LNC platform